MoneyWorks4Me

Aurobindo Pharma - Quaterly Results

09 Nov 2024 Evaluate
The company witnessed a 5.84% growth in the revenue at Rs. 28245.90 millions for the quarter ended September 2024 as compared to Rs. 26687.60 millions during the year-ago period.Good  Net Profit growth of 41.59% reported above the corresponding previous quarter figure of Rs. 3796.50 millions to Rs. 5375.30 millioins.Operating profit for the quarter ended September 2024 rose to 8435.40 millions as compared to 6122.60 millions of corresponding quarter ended September 2023.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202409 202309 % Var 202409 202309 % Var 202403 202303 % Var
Sales 28245.90 26687.60 5.84 52846.80 50595.80 4.45 106456.40 84570.00 25.88
Other Income 1226.60 670.80 82.86 1879.80 1624.20 15.74 6160.60 4439.20 38.78
PBIDT 8435.40 6122.60 37.77 14077.90 11299.20 24.59 28401.00 19488.30 45.73
Interest 516.30 366.90 40.72 1027.60 682.80 50.50 1826.00 745.80 144.84
PBDT 7919.10 5755.70 37.59 13050.30 10616.40 22.93 26575.00 18742.50 41.79
Depreciation 681.60 657.90 3.60 1350.40 1254.20 7.67 2545.80 2432.60 4.65
PBT 7237.50 5097.80 41.97 11699.90 9362.20 24.97 24029.20 16309.90 47.33
TAX 1862.20 1301.30 43.10 3034.20 2382.50 27.35 5028.20 3888.20 29.32
Deferred Tax -22.10 -70.40 -68.61 -46.70 -153.00 -69.48 -952.60 -233.40 308.14
PAT 5375.30 3796.50 41.59 8665.70 6979.70 24.16 19001.00 12421.70 52.97
Equity 580.80 585.90 -0.87 585.90 585.90 0.00 585.90 585.90 0.00
PBIDTM(%) 29.86 22.94 30.17 26.64 22.33 19.29 26.68 23.04 15.77
Peers
Company Name CMP
Sun Pharma. Inds. 1866.00
Dr. Reddys Labs. 1172.05
Cipla 1372.25
Lupin 2092.00
Zydus Lifesciences 1137.35
View more..